All patients deserve access to the right testing & treatment at the right time

From Testing to Targeted Treatment Program (FT3) is a collaborative program to make precision medicine a reality for all patients who could benefit from it.

All patients deserve access to the right testing & treatment at the right time

From Testing to Targeted Treatment Program (FT3) is a collaborative program to make precision medicine a reality for all patients who could benefit from it.

Program highlights

“Every day matters”: What it means to have a rare disease

Patients with rare disease often do not have a voice and rely on strong support from family, carers and trusted advocates.

2020 From Testing to Targeted Treatment Annual Report

Precision medicine (PM) can change patients’ lives, but its potential benefits have not yet been fully realized. Many challenges exist, from a lack of awareness to lack of access and evidence. 

Why accessing precision medicine can be an impossible task for those with a rare disease

February 28 2021 marks the fourteenth international Rare Disease Day coordinated by EURORDIS.

About us

Our motivation

All patients deserve access to the right testing & treatment at the right time. While Personalized and Precision Medicine (PM) can transform lives, its potential benefits have not yet been fully realized.

Our ambition

Our goal is to accelerate the benefits of PM by generating better evidence, creating awareness and building the conditions for better access to targeted medicine in oncology and beyond.

The partnership

We are an independent, nonprofit, global and multistakeholder consortium, building with patients for patients. Its members include individual patients, patient organizations, pharmaceutical & diagnostics companies, healthcare professionals and medical societies, payers, HTA bodies and regulators.

Keep up to date with developments from the precision medicine ecosystem

We don’t spam. Just key info at the right time.

Founding members